Amgen Inc. (AMGN) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $466.55 (+1.29%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 10, 2026 | Terence Flynn | Morgan Stanley | $326.00 | -30.1% |
| Mar 10, 2026 | Akash Tewari | Jefferies | $350.00 | -25.0% |
| Mar 5, 2026 | David Risinger | Leerink Partners | $355.00 | -23.9% |
| Jan 20, 2026 | Market Perform | Bernstein | $335.00 | -28.2% |
| Dec 3, 2025 | Evan Seigerman | BMO Capital | $372.00 | -20.3% |
| Nov 14, 2025 | David Amsellem | Piper Sandler | $381.00 | -18.3% |
| May 2, 2025 | Trung Huynh | UBS | $315.00 | -32.5% |
| Nov 12, 2024 | Michael Yee | Jefferies | $380.00 | -18.6% |
| Nov 12, 2024 | Olivia Brayer | Cantor Fitzgerald | $405.00 | -13.2% |
| Oct 21, 2024 | Terence Flynn | Morgan Stanley | $319.00 | -31.6% |
| Oct 16, 2024 | Salveen Richter | Goldman Sachs | $369.00 | -20.9% |
| Oct 7, 2024 | Carter Gould | Barclays | $315.00 | -32.5% |
| Sep 25, 2024 | Evan David Seigerman | BMO Capital | $362.00 | -22.4% |
| Sep 25, 2024 | Christopher Raymond | Raymond James | $344.00 | -26.3% |
| Sep 25, 2024 | Brian Skorney | Robert W. Baird | $215.00 | -53.9% |
| Aug 7, 2024 | Mohit Bansal | Wells Fargo | $335.00 | -28.2% |
| Aug 6, 2024 | Terence Flynn | Morgan Stanley | $303.00 | -35.1% |
| Jun 14, 2024 | Gregory Renza | RBC Capital | $332.00 | -28.8% |
| May 17, 2024 | Jay Olson | Oppenheimer | $380.00 | -18.6% |
| May 9, 2024 | Salim Syed | Mizuho Securities | $235.00 | -49.6% |
Top Analysts Covering AMGN
AMGN vs Sector & Market
| Metric | AMGN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.73 | 2.25 | 2.41 |
| Analyst Count | 49 | 8 | 19 |
| Target Upside | -13.4% | +153002.0% | +21.5% |
| P/E Ratio | 32.47 | 3.44 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $37.49B | $37.84B | $38.55B | 24 |
| 2027-03-31 | $8.54B | $8.98B | $9.26B | 7 |
| 2027-06-30 | $9.12B | $9.59B | $9.89B | 7 |
| 2027-09-30 | $9.29B | $9.77B | $10.08B | 7 |
| 2027-12-31 | $9.76B | $10.26B | $10.58B | 7 |
| 2028-03-31 | $8.98B | $9.44B | $9.74B | 6 |
| 2028-06-30 | $9.31B | $9.79B | $10.10B | 6 |
| 2028-09-30 | $9.43B | $9.92B | $10.23B | 6 |
| 2028-12-31 | $9.59B | $10.08B | $10.40B | 6 |
| 2029-12-31 | $39.94B | $41.03B | $42.70B | 25 |
| 2030-12-31 | $41.50B | $42.63B | $44.38B | 15 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $20.71 | $22.37 | $23.38 | 21 |
| 2027-03-31 | $4.95 | $5.29 | $5.50 | 10 |
| 2027-06-30 | $5.41 | $5.78 | $6.02 | 7 |
| 2027-09-30 | $5.42 | $5.79 | $6.03 | 7 |
| 2027-12-31 | $5.62 | $6.00 | $6.24 | 14 |
| 2028-03-31 | $5.52 | $5.89 | $6.13 | 11 |
| 2028-06-30 | $5.91 | $6.31 | $6.57 | 8 |
| 2028-09-30 | $5.77 | $6.16 | $6.41 | 8 |
| 2028-12-31 | $5.69 | $6.07 | $6.32 | 15 |
| 2029-12-31 | $24.42 | $25.29 | $26.63 | 4 |
| 2030-12-31 | $26.50 | $27.45 | $28.91 | 4 |
Frequently Asked Questions
What is the analyst consensus for AMGN?
The consensus among 49 analysts covering Amgen Inc. (AMGN) is Hold with an average price target of $393.17.
What is the highest price target for AMGN?
The highest price target for AMGN is $405.00, set by Olivia Brayer at Cantor Fitzgerald on 2024-11-12.
What is the lowest price target for AMGN?
The lowest price target for AMGN is $200.00, set by Steve Chesney at Atlantic Equities on 2021-04-28.
How many analysts cover AMGN?
49 analysts have issued ratings for Amgen Inc. in the past 12 months.
Is AMGN a buy or sell right now?
Based on 49 analyst ratings, AMGN has a consensus rating of Hold (2.73/5) with a -13.4% upside to the consensus target of $393.17.
What are the earnings estimates for AMGN?
Analysts estimate AMGN will report EPS of $22.37 for the period ending 2026-12-31, with revenue estimated at $37.84B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.